Back to Authors

Puschmann, Andreas

0000-0002-3201-8198

Mayo Clinic

Department of Clinical Sciences, Neurology, Lund University, 22100 Lund, Sweden.

Citations 18

Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders

Neurology | November 11, 2015 | Volume: 85 | Issue: 23 | Pages: 2016-2025

10.1212/wnl.0000000000002170 | PMID 26561290

Role for the microtubule-associated protein tau variant p.A152T in risk of α-synucleinopathies

Neurology | September 3, 2015 | Volume: 85 | Issue: 19 | Pages: 1680-1686

10.1212/wnl.0000000000001946 | PMID 26333800

DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients

European Journal of Neurology | August 17, 2015 | Volume: 22 | Issue: 9 | Pages: 1323-1325

10.1111/ene.12770 | PMID 26278106

BackgroundRecently, a novel mutation in exon 24 of DNAJC13 gene (p.Asn855Ser, rs387907571) has been reported to cause autosomal dominant Parkinson's disease (PD) in a multi‐incident Mennonite family.MethodsIn the present study the mutation containing exon of the DNAJC13 gene has been sequenced in a Caucasian series consisting of 1938 patients with clinical PD and 838 with pathologically diagnosed Lewy body disease (LBD).ResultsOur sequence analysis did not identify any coding variants in exon 24 of DNAJC13. Two previously described variants in intron 23 (rs200204728 and rs2369796) were observed.ConclusionOur results indicate that the region surrounding the DNAJC13 p.Asn855Ser substitution is highly conserved and mutations in this exon are not a common cause of PD or LBD among Caucasian populations.
Clinical Correlations With Lewy Body Pathology inLRRK2-Related Parkinson Disease

JAMA Neurology | November 17, 2014 | Volume: 72 | Issue: 1 | Pages: 100

10.1001/jamaneurol.2014.2704 | PMID 25401511

Alpha‐synuclein repeat variants and survival in Parkinson's disease

Movement Disorders | February 27, 2014 | Volume: 29 | Issue: 8 | Pages: 1053-1057

10.1002/mds.25841 | PMID 24578302

ABSTRACT Objectives To determine whether α‐synuclein dinucleotide repeat (REP1) genotypes are associated with survival in Parkinson's disease (PD). Methods Investigators from the Genetic Epidemiology of Parkinson's Disease Consortium provided REP1 genotypes and baseline and follow‐up clinical data for cases. The primary outcome was time to death. Cox proportional hazards regression models were used to assess the association of REP1 genotypes with survival. Results Twenty‐one sites contributed data for 6,154 cases. There was no significant association between α‐synuclein REP1 genotypes and survival in PD. However, there was a significant association between REP1 genotypes and age at onset of PD (hazard ratio: 1.06; 95% confidence interval: 1.01‐1.10; P value = 0.01). Conclusions In our large consortium study, α‐synuclein REP1 genotypes were not associated with survival in PD. Further studies of α‐synuclein's role in disease progression and long‐term outcomes are needed. © 2014 International Parkinson and Movement Disorder Society
Population‐specific frequencies for LRRK2 susceptibility variants in the genetic epidemiology of Parkinson's disease (GEO‐PD) consortium

Movement Disorders | August 2, 2013 | Volume: 28 | Issue: 12 | Pages: 1740-1744

10.1002/mds.25600 | PMID 23913756

ABSTRACTBackgroundVariants within the leucine‐rich repeat kinase 2 gene are recognized as the most frequent genetic cause of Parkinson's disease. Leucine‐rich repeat kinase 2 variation related to disease susceptibility displays many features that reflect the nature of complex, late‐onset sporadic disorders like Parkinson's disease.MethodsThe Genetic Epidemiology of Parkinson's Disease Consortium recently performed the largest genetic association study for variants in the leucine‐rich repeat kinase 2 gene across 23 different sites in 15 countries.ResultsHerein, we detail the allele frequencies for the novel risk factors (p.A419V and p.M1646T) and the protective haplotype (p.N551K‐R1398H‐K1423K) nominated in the original publication. Simple population allele frequencies not only can provide insight into the clinical relevance of specific variants but also can help genetically define patient groups.ConclusionsEstablishing individual patient‐based genomic susceptibility profiles that incorporate both risk factors and protective factors will determine future diagnostic and treatment strategies. © 2013 International Parkinson and Movement Disorder Society
Large-scale replication and heterogeneity in Parkinson disease genetic loci

Neurology | July 12, 2012 | Volume: 79 | Issue: 7 | Pages: 659-667

10.1212/wnl.0b013e318264e353 | PMID 22786590

A family with parkinsonism, essential tremor, restless legs syndrome, and depression

Neurology | May 9, 2011 | Volume: 76 | Issue: 19 | Pages: 1623-1630

10.1212/wnl.0b013e318219fb42 | PMID 21555728